Back

MXCT

0.00%
NEUTRAL

MaxCyte and Ori Biotech Collaborate to Improve Cell Therapy Manufacturing

Why we think this is neutral

This RNS announcement is a general update on a collaboration between MaxCyte and Ori Biotech, which does not contain any specific financial or operational details that would warrant a strong sentiment score. The announcement focuses on the companies' plans to integrate their technologies to enhance cell therapy manufacturing processes.

Key Points

  • MaxCyte and Ori Biotech to integrate their respective technologies to improve cell therapy manufacturing
  • The collaboration will focus on enhancing the yield and timelines for gene-edited T cell production
  • The companies aim to provide therapy developers with a powerful toolkit to achieve clinically relevant quantities of gene-edited T cells more rapidly and efficiently

Summary

The healthcare technology companies are collaborating to improve the efficiency and scalability of cell therapy manufacturing.

MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a cell-engineering focused company, and Ori Biotech, a manufacturing technology company, have announced a strategic collaboration to enhance efficiency, scalability, and productivity in cell therapy manufacturing. The collaboration will integrate MaxCyte's ExPERT™ platform and Flow Electroporation® technology with Ori's IRO® next-generation manufacturing platform to optimize the yield and streamline the manufacturing timelines of gene-edited primary T cells.

GENERAL UPDATE